#biotechnology #clinicalresearch #clinicaltrials #drugdevelopment #pharmaceuticals Boehringer, Zealand's survodutide posts 16.6% weight loss in late-stage trial ml.firstwordpharma.com To view or add a comment, sign in While the Phase III trial delivered impressive weight loss outcomes, survodutide's tolerabilty had raised a few eyebrows in a previous mid-stage study, wherein a substantial proportion of participants stopped treatment due to gastrointestinal side effects
Results vary based on your goals, peptide protocol, consistency, and overall health
Oxidized low-density lipoprotein in inflammation-driven thrombosis
Disclaimer: We request all readers, electronic media and others follow our citation guidelines when re-posting articles from farmdoc daily
Its table says an empty stomach is required for oral forms, while the tolerability section suggests taking the medication with an appropriately sized meal to improve comfort